L iver fibrosis (LF) is a global health problem and a critical process in liver disease as well as a major risk factor for progression to cirrhosis and hepatocellular carcinoma (HCC), one of the commonest and deadliest solid organ tumors.
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direct cellular toxicity of ethanol affects hepatocytes attributed to the fact that alcohol-detoxifying enzymes are mainly expressed in these cells. (5) Hepatocyte death leads to the release of cellular contents and reactive oxygen species that activate the liver-resident macrophages, the Kupffer cells (KCs), to release proinflammatory factors like tumor necrosis factor alpha (TNFa), interleukins (ILs; IL-1b and IL-6), and profibrogenic factors, especially transforming growth factor beta (TGFb). (6, 7) TGFb further drives the transdifferentiation of hepatic stellate cells (HSCs) to fibrogenic myofibroblast-like cells, (8) the main source of extracellular matrix proteins leading to fibrosis. (9) As a result of the complexity of the multicellular pathophysiology of LF, alternative pharmacological therapies that can reverse this disease or even halt progression to decompensated cirrhosis and HCC are still in an early developmental stage. (10) Understanding the molecular mechanisms underlying LF can provide clues on new treatments and drug development. On this basis, neddylation is a ubiquitin-like reversible posttranslational modification characterized by conjugation of Nedd8 (neural precursor cell expressed developmentally down-regulated 8) to its target proteins. Neddylation has been previously shown to be deregulated in many pathological conditions, including different types of cancer and Alzheimer's disease. (11, 12) The main targets of Nedd8 are the ubiquitin E3 ligase family of cullin-ring ligases (CRLs). Importantly, CRL substrates have important roles in cellular processes associated with inflammation as well as cell-cycle regulation, cancer cell growth, and survival pathways. (13) (14) (15) In recent years, several reports of noncullin neddylation targets indicate that Nedd8 might have additional biological functions. (16) In the liver context, several neddylation targets were found to be disrupted in liver tumors from HCC patients. (17) (18) (19) In spite of this, the relevance of neddylation modifications in LF, especially focusing on HSCs, the major fibrogenic cell type and highly refractive to current therapies, remained rather unexplored.
Our results show aberrant neddylation both in clinical and in two mouse models of LF, bile duct ligation (BDL) and CCl 4 chronic administration. Importantly, inhibition of neddylation in vivo caused a strong reduction in LF by affecting different liver cell types. On one hand, neddylation inhibition reduced hepatocyte death and inflammation in association with decreased KC activation. On the other hand, augmented neddylation characterizes activated HSCs, suggesting that neddylation inhibition could be important for resolving LF. Indeed, neddylation inhibition targets HSCs by inducing their apoptosis partly through accumulation of c-Jun, usually degraded by neddylated cullins. Overall, targeting neddylation in the several types of cells involved in LF is suggested as a potential and novel therapeutic approach for this disease.
Materials and Methods

HUMAN SAMPLES
Surgically resected specimens of well-characterized nonalcoholic fatty liver disease (NAFLD) patients from the Universitary Hospital Marqu es de Valdecilla (Santander, Spain), were used (n 5 15). Histological scoring was performed according to the NASH Clinical Research Network criteria. (20) Healthy human liver samples were used as controls (n 5 13). In these patients, fibrosis was staged from 0 to 4, being 0 5 none and 4 5 cirrhosis (Supporting Table S1 ). Another cohort of patients with or without fibrosis diagnosed by an expert pathologist was used for western blotting analysis (n 5 4 nonsignificant fibrosis, n 5 7 significant fibrosis staging 3). Finally, a cohort of alcoholic and viral fibrosis samples from the Universitary Hospital of Modena (Modena, Italy) were also analyzed (n 5 5 control, n 5 7 hepatitis B infection, and n 5 6 alcohol abuse). Patients gave informed consent to all clinical investigations, which were performed in accord with the principles embodied in the 1975 Declaration of Helsinki in a priori approval by the institutional human research review committee.
BDL AND CCl 4 ANIMAL MODELS AND IN VIVO DRUG TREATMENT
Adult male C57BL/6J mice were acquired from Charles River Laboratories (Barcelona, Spain) and housed in the animal facility at our center, the CIC bioGUNE (Derio, Spain). Animal procedures were approved by the CIC bioGUNE Animal Care and Use Committee according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the NIH (publication 86-23, revised 1985) . BDL was performed as described. (21) BDL mice were treated with MLN4924 (Millennium Pharmaceuticals, Cambridge, MA), starting at 3 or 7 days post-BDL procedure, by subcutaneous injection at a dose of 60 mg/kg once a week, following the Millennium Corporation communication (Supporting Fig.  S1A,B) . Twenty-one days post-BDL, animals were sacrificed. Overall survival rate in the BDL group was 60% at 21 days of BDL against 100% in the MLN4924 treatment groups. CCl 4 (Sigma-Aldrich, St. Louis, MO) was administered by intraperitoneal injection at a dose of 0.6 mL/kg once a week. Two weeks after the first CCl 4 administration, MLN4924-treatment, by subcutaneous injection at a dose of 60 mg/ kg once a week, was started (Supporting Fig. S1C ). After 4 weeks of MLN4924 treatment, animals were sacrificed. Upon sacrifice, blood was withdrawn and livers extracted and analyzed as detailed in the Supporting Methods.
CELL MODELS
Mouse primary hepatocytes, KCs, and HSCs were isolated either from healthy control or 7-day BDL mice as described. (22) Briefly, mouse livers were perfused with collagenase (Worthington Biochemical Company, Freehold, USA) and hepatocytes isolated following a standard centrifugation. KCs and HSCs were isolated after Percoll Plus (GE Healthcare, Little Chalfont, UK) gradient centrifugation and selective adherence. The human HSC line, LX-2 (Millipore Corporation, Darmstadt, Germany), was used and cultured as described. (23) Cell treatments are detailed in the Supporting Methods.
STATISTICAL ANALYSIS
Quantitative data are plotted as mean 6 SEM. Statistical significance was estimated using one-way analysis of variance when more than two groups were compared and the Student t test for comparison between two groups. P < 0.05 was considered statistically significant.
Results
ALTERED NEDDYLATION IN LF
Deregulated neddylation has been implicated in many pathological conditions. (11, 12) Here, immunohistochemical (IHC) analysis of livers from a cohort of NAFLD patients with significant fibrosis evaluated by an expert pathologist and classified either as low or moderate fibrosis, showed increased hepatic neddylation (measured both as levels of global protein neddylation and of the Nedd8 activating enzyme E1 subunit 1 [NAE1], an essential component initiating the transfer cascade of the Nedd8 conjugation pathway; Fig. 1A and Supporting Fig. S2 ; Supporting Table S1 ). These results were confirmed by western blotting analysis of levels of neddylated cullins, used as a surrogate for global protein neddylation (Fig. 1B) . Increased neddylation activity in fibrosis is not dependent on etiology, given that its induction was also observed in fibrosis originating from hepatitis B infection or alcohol abuse (Supporting Fig. S3 ). Even though the neddylation levels appear to be dependent of the different etiologies underlying fibrosis development, further experiments are necessary to investigate whether this correlates with disease severity. Neddylation was also measured in experimental models recapitulating the key steps of fibrosis clinical progression, such as BDL, the most frequently used macrosurgical extrahepatic cholestasis experimental model, (24) and in the well-established toxic model of CCl 4 -induced liver fibrosis. (25) Both global protein neddylation and NAE1 expression levels measured by IHC (Fig. 1C,D) , as well as neddylated cullins measured by western blotting were increased at 21 days after BDL and after 6 weeks of CCl 4 ( Fig.  1E ,F). Of note, neddylation was induced already at day 3 after BDL and 2 weeks of CCl 4 administration, suggesting that increased neddylation is an early event in liver injury (Supporting Fig S4A,C) . Increased neddylation was only observed at the posttranslational level, without significant changes at the messenger RNA (mRNA) level of either NEDD8 or NAE1 in the clinical and animal models of fibrosis used (Supporting Fig. S5A-C) .
LF is a multistep process involving different cell types. Interestingly, double immunofluorescence staining for Nedd8 and albumin, a hepatocyte marker, were colocalized in mouse liver post-BDL. Likewise, activated KCs expressing F4/80, a macrophage marker, and activated HSCs expressing desmin and alpha smooth muscle actin (aSMA) colocalized with Nedd8 staining after BDL-induced injury. These findings were confirmed by western blotting after isolation of the different cell types either from control or BDLinduced fibrotic mouse livers ( Increased neddylation in the BDL and CCl 4 fibrotic mouse models prompted us to investigate the impact of neddylation inhibition in these animals. For this purpose, we used MLN4924, a first-in-class inhibitor of NAE1 that has recently entered clinical trials for cancer therapy both in solid and nonsolid tumors. BDL mice were treated once a week with MLN4924 starting at 3 or 7 days postsurgery and ending at 21 days (BDL MLN4924 3 days and BDL MLN4924 7 days), time points characterized either by cell death and inflammation or fibrosis onset, respectively (Supporting Fig. S4A,B) . MLN4924 treatment was also administered to CCl 4 rodents from 2 to 6 weeks of the initial CCl 4 administration, a time point where cell death, inflammation, and fibrosis coexist (Supporting Fig. S4C ). As expected, MLN4924 treatment decreased neddylation in both animal models studied ( Fig. 1C-F) .
NEDDYLATION INHIBITION AMELIORATES BA-AND CCl 4 -INDUCED CELL DEATH
Both intrahepatic BA overload (24) and the metabolization of the toxic CCl 4 (25) result in liver injury. Metabolomic analysis of mouse livers revealed that 21 days post-BDL, both primary hepatic BA, such as cholic acid, and taurine-conjugated BA (tauroursodeoxycholate and taurodehydrocholic acid), were significantly increased relative to control animals, whereas pharmacological treatment with MLN4924 starting 3 days post-BDL had no effect on hepatic BA concentration (Supporting Fig. S7 ). In spite of unaltered BA hepatic content, neddylation inhibition in vivo post-BDL significantly decreased accumulation of celldeath-related markers, such as parenchymal disruption and augmented terminal deoxynucleotide transferase dUTP nick end labeling (TUNEL) and caspase 3 cleavage (Fig. 3A) with reduction of serum transaminases levels (Fig. 3B) . Also, MLN4924 treatment to BDL rodents reduced the activation of the proapoptotic and necrotic stress-activated kinase, c-Jun Nterminal kinase (JNK), and p53 death activator as well as of mRNA levels of genes involved in death regulation, such as b-cell lymphoma 2 (Bcl-2) and the Bcl-2 associated protein X (Bax), being the first previously described as an adaptive response to resist BAinduced apoptosis (26) (Fig. 3C,D) . Contrary to previous studies in cancer reporting activation of p53 by MLN4924, (27) MLN4924 treatment post-BDL reduced hepatic p53, an effect that we ascribe to an overall improved liver phenotype. Decreased cell death markers and serum transaminases upon MLN4924-treatment were also observed in CCl 4 -induced LF in mouse (Fig. 4A,B) .
LF is a multicellular complex process where hepatocyte death mediated by BA plays an important initiation role. (2, 4) Thereby, to assess the direct actions of neddylation inhibition in hepatocyte cell death, we isolated primary mouse hepatocytes and treated them with the toxic bile acid, DCA (deoxycholic acid). Similar to our in vivo results, where neddylation was increased in hepatocytes from BDL-injured mouse livers ( Fig. 2 and Supporting Fig. S6A ), neddylation was induced 30 minutes to 1 hour following DCA stimulation in isolated healthy mouse hepatocytes (Fig. 3E) . Treatment with DCA significantly increased cell apoptosis, measured as caspase 3 activity (Fig. 3F) . This is in agreement with earlier evidence where increased death as a result of necrosis was observed in BDL, whereas high toxic BA was shown to induce apoptosis in cultured hepatocytes. (28) Of note, neddylation inhibition either by MLN4924-treatment or Nae1 silencing significantly reduced caspase 3 activity only in DCA-stimulated hepatocytes not inducing apoptosis per se, indicating that neddylation inhibition-mediated cell death is exclusively of dividing hepatoma cells or pretumoural hepatocytes, as observed. (17) Overall, these data suggest that neddylation could mediate hepatocyte death in liver injury.
NEDDYLATION INHIBITION DECREASES LIVER INFLAMMATION
Upon death-induced stimulus, hepatocytes release factors that promote the activation of the liver resident macrophages. Thus, increased accumulation of F4/80, a cell membrane marker of hepatic macrophages, was observed in the mouse models of liver injury studied. Of relevance, diminished F4/80 staining indicated that neddylation inhibition in vivo decreased KC accumulation both in BDL-and CCl 4 -induced liver injury (Figs. 4C and 5A ). MLN4924 treatment to BDL rodents diminished expression of proinflammatory cytokines, such as TNFa, and its receptor, TNFa receptor 1 (TNFR1), previously implicated in liver damage (29) (Fig. 5B ) and accounted for reduced expression at the mRNA level of inducible nitric oxide synthase (Nos2), the chemokine (C-X-C motif) ligand 1 (Cxcl1) and the C-C chemokine receptors, Ccr1, Ccr2, and Ccr5 (Fig. 5C ).
Different liver cell types interact and play important roles on inflammation mediation. Herein, neddylation inhibition prevented stimulation of inflammatory markers, such as chemokine (C-X-C motif) ligand 2 (Cxcl2) and chemokine (C-C motif) ligand 2 (Ccl2), in primary mouse hepatocytes treated with DCA (Fig.  5D ). On the other hand, previous studies have reported that lipopolysaccharide (LPS)-activated macrophages have increased neddylation activity, (14) an outcome similar to our in vivo findings of increased neddylation in activated KC (Fig. 2) . In vitro treatment with MLN4924 to isolated KCs after stimulation with LPS reduced IL-6 and TNFa cell release, as well as mRNA levels of Il-6, Il1b, Tnfa, and Nos2 (Fig. 5E) . Likewise, neddylation inhibition in isolated KCs from injured livers decreased mRNA levels of Ccl2 and Ccr2, molecules involved in CC-chemokine recruitment of macrophages (30) (Fig. 5F ). Altogether, our data suggest that neddylation can modulate inflammation after hepatic injury.
NEDDYLATION PLAYS A ROLE IN HSC ACTIVATION
As a result of maintained hepatocyte cell death and hepatic inflammation, quiescent HSCs undergo a differentiation process toward an activated state, becoming the main fibrogenic cell type in the damaged liver. (8) Thus, HSC accumulation (desmin staining) and, more important, its activation (aSMA staining), with concomitant accumulation of collagen deposits (Sirius Red staining and hydroxyproline assay), were increased after BDL-and CCl 4 -induced injury. MLN4924 treatment in vivo, starting either at 3 or 7 days post-BDL and after 2 weeks of CCl 4 chronic administration, showed a reduction of HSC activation and collagen deposition (Figs. 4D,E and 6A,B) . Of note, the decrease was more significant in the BDL model probably because 3 and 7 days post-BDL is an initial stage of the fibrosis progression against the CCl 4 model where fibrosis is more advanced at 2 weeks after CCl 4 chronic administration (Supporting Fig. S4B,C) . Thereby, we hypothesize that, at least in the BDL mouse model, MLN4924 treatment acts both by preventing and reducing activation of HSCs. Moreover, neddylation inhibition in BDL-induced liver injury reduced the levels of the profibrogenic factor, TGFb, both at protein and mRNA level, and expression of collagen type I alpha 1 (Col1a1), and the matrix metalloproteinase 9 (Mmp9) accounting for matrix degradation (Fig. 6C,D) .
Even though reduced activation of HSC and concomitant lowering fibrosis resulting from neddylation inhibition in vivo can be a consequence of decreased hepatocyte cell death and hepatic inflammation, our aforementioned in vivo findings indicate that activated HSCs show increased neddylation activity (Fig. 2) . Indeed, we observed, in a model of mouse primary HSC cultured on uncoated plastic, (31) an increase in activation markers, such as collagen (Col1a2) and TGFb (Tgfb1), in association with increased protein neddylation levels (Fig. 7A) . Likewise, when comparing cultures of in vivo activated and nonactivated primary mouse HSCs, induced expression of activation markers correlates with increased neddylation (Fig. 7B) . Also, when we stimulated the human LX-2 cell line, (23) neddylation was induced as activation markers were augmented in response to TGFb stimulus (Fig. 7C) . Overall, these data indicate that activated HSC are characterized by increased neddylation activity.
NEDDYLATION INHIBITION DECREASES FIBROSIS BY INDUCING HSC APOPTOSIS
Reduced activation of HSCs is the main objective of therapeutic strategies targeting fibrosis. On this basis, MLN4924 treatment in vivo starting at 7 days after BDL, when HSCs are already activated (Supporting Fig 4SB) , showed a reduction of HSC accumulation and activation together with decreased collagen deposition (Fig. 6A,B,D) . Furthermore, in vitro treatment with MLN4924 to either in vivo activated mouse primary HSCs or TGFb-stimulated human LX-2 cells induces apoptosis, as assessed by caspase 3 activity assay (Fig. 8A,D) , suggesting that apoptosis of activated HSC plays a role on fibrosis reversibility. MLN4924-induced apoptosis in HSC isolated from healthy animals is significantly lower than observed in activated HSC (Fig. 8C) . Previous reports have shown that c-Jun, a signal-transducing transcription factor of the activator protein 1 family, normally implicated in cell-cycle progression, differentiation, and cell transformation, is linked to apoptosis in several types of cells, (32) including HSCs. (33) Importantly, c-Jun is degraded by neddylated cullins, (34) highlighting that neddylation inhibition could somehow modulate c-Jun levels and concomitant apoptosis. Indeed, c-Jun levels are induced upon MLN4924-treatment (Fig. 8B,E) and, more important, in TGFb-stimulated LX-2 cells, partial silencing of c-Jun is able to reduce the apoptotic-induced actions of MLN4924 (Fig. 8F ).
These evidences suggest that the accumulation of cJun as a result of neddylation inhibition is an important mediator of HSC apoptosis.
Discussion
LF is a critical process in liver disease, a global health problem with complex pathophysiology and currently without therapeutical approaches that can successfully reverse, or at least halt, its progression to cirrhosis and HCC. The identification of potential therapeutic molecular and pathway-specific targets involved in the development and/or progression of LF is crucial for the discovery of novel pharmacological agents. Deregulated neddylation is often associated with many pathological conditions. (11, 12) Previously, other investigators have shown that Cullin 7, a welldescribed Nedd8 substrate, is a novel gene potentially involved in liver carcinogenesis, (35) an end stage of LF. Moreover, our group has recently shown that neddylation activity is aberrant in HCC. (17) Herein, we provide strong evidence that neddylation is up-regulated in clinical LF from different etiologies as well as in two distinct animal models that mimic the progression of fibrosis observed in patients, the BDL-and the CCl 4 -induced liver injury. Both in clinical and in vivo studies, the up-regulation of neddylation is stringent to the protein level, contrary to earlier evidence in liver and lung cancer where mRNA levels of NEDD8 and NAE1 were up-regulated in correlation with increased global protein neddylation. (11, 17) We speculate that the increase in mRNA levels of the Nedd8 system in cancer may result from the important role that neddylation plays in cell-cycle progression under these circumstances.
Hepatocyte death is an early event in the pathology of liver injury, (2) leading to the recruitment and activation of KCs following the engulfment of apoptotic bodies released from dying hepatocytes. As a consequence, KCs express cytokines, which further induce death-receptor-mediated apoptosis in hepatocytes. and (F) caspase-3 activity of 6-hour 50-lM DCA-stimulated primary mouse hepatocytes treated with MLN4924 or after Nae1 silencing. Western blotting was used to confirm Nae1 silencing (lower right panel). Control (n 5 5), 21 days BDL (n 5 10), and MLN4924 (treated 3 days postsurgery [n 5 5]). *P < 0.05 and ***P < 0.001 versus control and # P < 0.05, ## P < 0.01 and P < 0.001 MLN4924 treated versus BDL treatment are indicated. At least triplicates were used for each in vitro experimental condition. Abbreviations: ALT, alanine aminotranferase; AST, aspartate aminotransferase; a.u., arbitrary units; d, days; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; h, hour(s); pJNK, phosphorylated JNK. Herein, we observed that neddylation inhibition in vivo diminished apoptosis and inflammation markers in mouse livers. These results were further validated in vitro, where MLN4924 treatment to DCA-stimulated isolated mouse hepatocytes decreased apoptotic and inflammatory markers as well as chemokine expression. Also, neddylation inhibition decreased cytokine release and reduced the accumulation of chemokine receptors both in LPS-stimulated KCs and in in vivo activated mouse KCs. Overall, these results highlight that neddylation inhibition plays a protective role in injured hepatocytes, an effect contrary to the well-described proapoptotic role of MLN4924 on tumoral cells, (13) while decreasing macrophage activation. Previously, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) was described to play a role both in
Neddylation plays a role in HSC activation. Activation markers and western blotting analysis of neddylated cullins in (A) plastic activated mouse primary HSCs at 3 and 7 days of culture, (B) mouse primary HSCs isolated either from control or BDLinjured mouse livers and; and (C) in human LX-2 cells either nonstimulated or after TGFb stimulus. At least triplicates were used for each in vitro experimental condition. *P < 0.05, **P < 0.01, and ***P < 0.001 are indicated. Abbreviations: ACTA2, actin, alpha 2, smooth muscle, aorta; d, days; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
hepatocyte apoptosis (36) and KC activation, (37) where regulation of NF-jB signaling functions as a primary pathway by which infectious agents like LPS cause upregulation of proinflammatory cytokines. (14) NF-jB is a protein complex that controls transcription of DNA and is found to be involved in inflammation. (38) Importantly, neddylation plays a role on NF-jB activation by promoting its nuclear translocation through SCF bTrCP , a CRL that targets the NF-jB inhibitory protein, inhibitor of kappa B alpha. (16) We speculate that neddylation inhibition in hepatocytes and in KCs could result in reduced NF-jB translocation to the nucleus and thereby decreased expression of specific NF-jB-target genes. (38) Further experiments are necessary to elucidate the role of NF-jB in the anti-inflammatory effect of neddylation inhibition both in hepatocytes and KCs. (C) MLN4924-induced caspase 3 activity in isolated primary mouse HSCs from either control or BDL rodents. (F) c-Jun silencing is able to reduce MLN4924-induced cell death in TGFb-stimulated LX-2 cells. At least triplicates were used for each in vitro experimental condition. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control and ### P < 0.001 versus siCtrl are indicated. Abbreviations: a.u., arbitrary units; d, days; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
As a result of a maintained hepatocyte cell death and hepatic inflammation in liver injury, quiescent HSCs undergo a differentiation process toward an activated state, becoming the main fibrogenic cell type in the liver. (8) Herein, we have observed that neddylation inhibition in vivo is able to reduce HSC activation both in the BDL-and CCl 4 -induced liver injury mouse model. Even though decreased hepatocyte death and reduced hepatic inflammation may partly account for these observations, we provide strong evidence that neddylation is specifically induced in activated HSCs. TGFb is a pleiotropic cytokine with an important role in HSC activation signaling through transmembrane receptor serine/threonine kinases that activate SMAD2 proteins. (39) TGFb ligand first binds to the type II receptor (TbRII) at the plasma membrane, leading to the formation of the TbRI-TbRII complex, in which TbRII phosphorylates TbRI. The activated TbRI, in turn, phosphorylates Smad2 and Smad3, which then forms a complex with Smad4; this complex then translocates to the nucleus to regulate target gene expression. (40) Recent evidence highlights that the Casitas B-lineage lymphoma can act as a Nedd8 E3 ligase of TbRII to prevent its ubiquitination-dependent degradation in blood cells. (41) Under these circumstances, increased neddylation could play a role on TGFb signaling in HSCs by promoting the stabilization of the TbRII. In summary, our data implicate the posttranslational modification of neddylation in HSC activation by mechanisms not totally understood.
Even though we demonstrate that neddylation inhibition in vivo and in vitro prevents activation of HSCs, from the clinical point of view, the main interest lays in a therapeutic approach that can revert fibrosis. Previous reports indicate that both deactivation of HSCs to a more quiescent state (42, 43) or apoptosis of activated HSCs (44) could account for fibrosis reversion. By using the pharmacological agent, MLN4924, we show that neddylation inhibition in vitro induces apoptosis of activated HSCs. This approach is advantageous, considering some recent evidence highlighting that HSC reversion, even though it can lead to resolution of fibrosis, can result in higher responsiveness of reverted HSCs to recurring fibrogenesis stimulus. (43) Very recently, c-Jun has been linked to the apoptosis of HSCs. (33) In agreement, induced apoptosis as a result of neddylation inhibition is concomitant with augmented levels of c-Jun, and, more important, c-Jun silencing protects LX-2 cells from MLN4924-induced apoptosis. c-Jun accumulation after neddylation inhibition is most probably a consequence of the fact that c-Jun was shown to be degraded by neddylated cullins. (34) Overall, our results show a deregulation of the neddylation pathway both in clinical and in experimental mouse models of LF. More important, the inhibition of neddylation in vivo reverses LF by an encompassing process influencing almost every aspect of liver damage. On one hand, neddylation inhibition results in reduced hepatocyte death and inflammation in association with decreased KC activation and, on the other hand, induces the apoptosis of activated HSCs promoting the regression of fibrosis. Overall, targeting of the neddylation pathway is suggested as a potential and novel therapeutic approach in LF.
